Literature DB >> 15252308

Immunophenotypic differences between intestinal-type and low-grade papillary sinonasal adenocarcinomas: an immunohistochemical study of 22 cases utilizing CDX2 and MUC2.

Helen P Cathro1, Stacey E Mills.   

Abstract

Nonsalivary sinonasal adenocarcinomas can be divided into low-grade and high-grade tumors. The former are often papillary and the latter are usually of intestinal type, morphologically similar to metastatic colonic carcinoma. Antibodies to CDX2, a transcription factor gene highly specific for intestinal adenocarcinomas, MUC2, a mucin gene expressed in adenocarcinomas from various sites, and cytokeratins (CK) 7 and 20 were used to examine the two groups of tumors. Formalin-fixed, paraffin-embedded tissue from 22 sinonasal adenocarcinomas was reclassified into 9 high-grade intestinal-type, 3 high-grade nonintestinal, and 10 low-grade, predominantly papillary adenocarcinomas. Immunohistochemical staining was graded on a 0 to 4+ scale with 5% or greater tumor cell staining considered positive. Of the high-grade intestinal group, 78% demonstrated 4+ CDX2 positivity, with 44% MUC2 positive. Although 89% of this group was CK7 positive, the percent of staining was variable. A majority (67%) of the intestinal cases was 4+ CK20 positive. Almost every nonintestinal adenocarcinoma (90%) (low- and high-grade) was CK7 positive (7 of 9, 4+), without expression of any of the three colonic adenocarcinoma markers. The three high-grade nonintestinal tumors had the expression profile of the low-grade papillary group with the exception of focal MUC2 positivity in 1 case. Intestinal-type adenocarcinomas have an expression profile distinct from nonintestinal sinonasal adenocarcinomas. The former are similar, but not identical, to colonic adenocarcinomas. Immunohistochemical staining for CDX2, MUC2, and differential cytokeratins does not differentiate metastatic colorectal from primary sinonasal intestinal-type adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252308     DOI: 10.1097/01.pas.0000126856.09058.71

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  8 in total

1.  Update on sinonasal adenocarcinoma: classification and advances in immunophenotype and molecular genetic make-up.

Authors:  Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2007-11-28

2.  Intestinal-type adenocarcinoma arising in a congenital sublingual teratoid cyst.

Authors:  Abbas Agaimy; Beate Raab; Viktor Bonkowsky; Peter H Wünsch
Journal:  Virchows Arch       Date:  2007-02-07       Impact factor: 4.064

3.  Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Edward B Stelow; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2017-02-28

4.  A Subset of Sinonasal Non-Intestinal Type Adenocarcinomas are Truly Seromucinous Adenocarcinomas: A Morphologic and Immunophenotypic Assessment and Description of a Novel Pitfall.

Authors:  Bibianna Purgina; Jassem M Bastaki; Umamaheswar Duvvuri; Raja R Seethala
Journal:  Head Neck Pathol       Date:  2015-02-19

5.  Among sinonasal tumors, CDX-2 immunoexpression is not restricted to intestinal-type adenocarcinomas.

Authors:  Matthew P Tilson; Gary L Gallia; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-07-12

Review 6.  Intestinal-Type Adenocarcinoma: Classification, Immunophenotype, Molecular Features and Differential Diagnosis.

Authors:  Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2017-03-20

7.  Reappraisal of Grading in Intestinal-Type Sinonasal Adenocarcinoma: Tumor Budding as an Independent Prognostic Parameter.

Authors:  Christian M Meerwein; Muriel D Brada; Michael B Soyka; David Holzmann; Niels J Rupp
Journal:  Head Neck Pathol       Date:  2022-01-11

Review 8.  Sinonasal Adenocarcinoma: Update on Classification, Immunophenotype and Molecular Features.

Authors:  Ilmo Leivo
Journal:  Head Neck Pathol       Date:  2016-02-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.